IL18 and neoplasm: GM-CSF production seems to have a synergistic effect with Toll-Like Receptor—2 (TLR2) to inhibit tumor growth and modulate tumor-infiltrating Antigen Presenting Cells (APCs) [74], and IL-18 has been associated with better survival rates in cancer patients [75].